TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9737760
Drug: Acetazolamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500 mg sustained-release capsule once daily) plus low-dose dexamethasone (4 mg every 12 h)
Study: 9737760
Drug: Acetazolamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500 mg once daily) plus placebo (every 12 h)
Study: 7977146
Drug: Milk chocolate
Normalized name: Meritene Milk Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk chocolate bar (46 g)
Study: 2593864
Drug: Norethisterone acetate
Normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone acetate 1 mg (Group A)
Study: 2593864
Drug: Norethisterone acetate
Normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone acetate 0.5 mg (Group B)
Study: 2593864
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 5 mg (Group C)
Study: 2593864
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 2.5 mg (Group D)
Study: 2593864
Drug: High progestogen
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High progestogen doses (Norethisterone acetate 1 mg and Megestrol acetate 5 mg)
Study: 2593864
Drug: High progestogen
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High progestogen doses (Norethisterone acetate 1 mg and Megestrol acetate 5 mg) with women under 67 kg or last menstruation over 5 years ago
Study: 30192327
Drug: Intravenous furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous furosemide plus enhanced recovery after surgery on postoperative day 1 and 2
Study: 15881949
Drug: Pneumo 23
DrugBank: Streptococcus pneumoniae type 33F capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB16711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumo 23 vaccine
Study: 19025058
Drug: Aniracetam (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aniracetam (400 mg, 2 x 200 mg/capsule)
Study: 19025058
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of Aniracetam (400 mg)
Study: 11473680
Drug: Montelukast (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (active treatment)
Study: 10028858
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (2.2 mg/kg/day for 3 weeks, tapered within 1 week) followed by rIFN-alpha (same dose as above)
Study: 8015423
Drug: Naftidrofuryl (vasoactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (vasoactive drug) administered postoperatively
Study: 2778114
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied corticosteroid formulations of different potencies
Study: 31573086
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (no EIPL)
Study: 28279542
Drug: Ketamine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.3 mg/kg via intravenous piggyback over 15 min
Study: 25080450
Drug: Daclatasvir 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 20 mg
Study: 24451151
Drug: Daclatasvir 60
Normalized name: daclatasvir 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 60 mg
Study: 25080450
Drug: Daclatasvir 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 20 mg (Genotype 4)
Study: 25080450
Drug: Daclatasvir 60
Normalized name: daclatasvir 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 60 mg (Genotype 4)
Study: 19826270
Drug: Fluid resuscitation
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid resuscitation guided by hourly urine output
Study: 16477215
Drug: Lipid formulation
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid formulation of AmB (Control)
Study: 10796750
Drug: Other drugs
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drugs (Gabapentine, Clonidine, Diazepam, Amytal, oral Baclofen)
Study: 2873015
Drug: Drug-treated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-treated group (hydrochlorothiazide, propranolol, methyldopa)
Study: 2873015
Drug: Drug-treated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-treated group
Study: 29626416
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of 16 mU/min (Group I)
Study: 29626416
Drug: 5 mU/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mU/min quarter‐hourly (Group IV)
Study: 22401642
Drug: Rotigotine 3
Normalized name: ROTIGOTINE 3MG/24HRS PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine 3 mg/24 hours via transdermal patch
Study: 22401642
Drug: Rotigotine 8
Normalized name: ROTIGOTINE 8MG/24HRS PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine 8 mg/24 hours via transdermal patch
Study: 22401642
Drug: Single large
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single large patch vs. 2 smaller patches
Study: 22401642
Drug: Patch application
Normalized name: Patch
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch application sites (hip, shoulder, abdomen, flank, thigh, upper arm)
Study: 11930708
Drug: Maxillary expansion
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary expansion and protraction therapy
Study: 2874085
Drug: Cefazolin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (3 doses of 0.5 g)
Study: 2874085
Drug: Mezlocillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin (3 doses of 1 g)
Study: 22166848
Drug: Combined intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined intensive treatment of glycemia and blood pressure
Study: 19384953
Drug: SLC45A2 1721
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLC45A2 1721 C>G
Study: 19384953
Drug: ASIP g.8818
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASIP g.8818 A>G
Study: 19384953
Drug: Haplotype near
Normalized name: OCTINOXATE 3.5 mg in 1 mL / TITANIUM DIOXIDE 1.9 mg in 1 mL TOPICAL LIQUID [Revlon Nearly Naked Makeup]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haplotype near ASIP (rs4911414[T] and rs1015362[G])
Study: 17465473
Drug: Hyoscine butyl
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butyl bromide injection
Study: 11094012
Drug: 0.06 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg/kg rocuronium (adults)
Study: 11094012
Drug: 0.12 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 mg/kg rocuronium (children)
Study: 11094012
Drug: 0.12, 0.18,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12, 0.18, or 0.24 mg/kg rocuronium (children)
Study: 11094012
Drug: 0.06, 0.12,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06, 0.12, or 0.18 mg/kg rocuronium (adults)
Study: 8354583
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg daily for 7 days
Study: 3720527
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and d-amphetamine combination
Study: 26239594
Drug: Partly supervised
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Partly supervised exercise programme (6 weeks supervised, followed by 6 weeks self-administered)
Study: 26239594
Drug: Self-administered exercise
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered exercise programme (12 weeks)
Study: 12657224
Drug: Clomipramine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine infusion (5mg in 5min) during head-up tilt test (Clom-HUT)
Study: 12657224
Drug: Clomipramine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine infusion during tilt test
Study: 9193243
Drug: Low-dose indomethacin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose indomethacin sodium for the prevention of intraventricular hemorrhage
Study: 9193243
Drug: Chorioamnionitis, treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chorioamnionitis, treatment with surfactant, bronchopulmonary dysplasia, abnormal cranial US findings
Study: 1586272
Drug: Standard-range lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-range lithium levels (0.8 to 1.0 mmol/L)
Study: 1586272
Drug: Low-range lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-range lithium levels (0.4 to 0.6 mmol/L)
Study: 1586272
Drug: Standard-range lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-range lithium therapy
Study: 31098961
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine infusion (5 mg·kg−1)
Study: 31098961
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo infusion (diphenhydramine 50 mg)
Study: 27107066
Drug: All RSB
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All RSB groups (single-dose, repeated-dose, continuous infusion)
Study: 25060946
Drug: Olmesartan medoxomil/amlodipine
Normalized name: olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide 40 mg-5 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan medoxomil/amlodipine 20/5 mg
Study: 21282560
Drug: Olmesartan 40
Normalized name: HCTZ 25/OLMESARTAN 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 40 mg
Study: 19149823
Drug: Rimonabant plus
Normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Rimonabant plus nicotine patch (n = 369)
Study: 19149823
Drug: Rimonabant plus
Normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Rimonabant plus placebo patch (n = 366)
Study: 19149823
Drug: Rimonabant plus
Normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Rimonabant plus nicotine patch
Study: 15382410
Drug: Static magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Static magnetic therapy
Study: 10071698
Drug: 5-mL injectate
Normalized name: von Willebrand factor
DrugBank: Von Willebrand factor human (DB13133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mL injectate
Study: 10071698
Drug: 10-mL injectate
Normalized name: von Willebrand factor
DrugBank: Von Willebrand factor human (DB13133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mL injectate
Study: 10071698
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 5-mL and 10-mL injectates
Study: 7027894
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg metoprolol
Study: 28580646
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg subcutaneously
Study: 26376074
Drug: Stress dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress dose hydrocortisone (tapering 7-day course)
Study: 26376074
Drug: Stress dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress dose hydrocortisone
Study: 19623694
Drug: Posaconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d alone)
Study: 19623694
Drug: Posaconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d) and Ritonavir (100 mg/d)
Study: 19623694
Drug: Posaconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d)
Study: 19623694
Drug: Posaconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d) and Efavirenz (400 mg/d)
Study: 17277393
Drug: Targeted cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted cancer therapies (specifics not provided)
Study: 15077933
Drug: Acupuncture with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture with continued symptomatic medication (Group B)
Study: 15077933
Drug: Symptomatic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic medication followed by acupuncture (Group C)
Study: 11910689
Drug: Esmolol intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol intravenous (i.v.) at the dose of 150 micrograms.kg‐1
Study: 2979286
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg b.d. for 4 weeks
Study: 26252788
Drug: fedratinib 300
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fedratinib 300 mg once daily
Study: 26252788
Drug: fedratinib 400
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fedratinib 400 mg once daily
Study: 26252788
Drug: fedratinib 500
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fedratinib 500 mg once daily
Study: 23337693
Drug: Rivaroxaban (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (dose not specified)
Study: 21174055
Drug: Orofacial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orofacial therapy
Study: 21174055
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no orofacial therapy)
Study: 10553838
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 STIM: 24 patients received a single injection of 20 mL of a mixture of 2% lidocaine and 0.5% bupivacaine with 1:200,000 epinephrine.
Study: 10553838
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 STIM: 26 patients received 10 mL of the same solution injected after stimulation of each sciatic nerve component.
Study: 1677903
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cetirizine administered orally
Study: 1677903
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cetirizine administered sublingually
Study: 1677903
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cetirizine administered orally or sublingually
Study: 375686
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg imipramine
Study: 26541814
Drug: Cariprazine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 0.75 mg/day
Study: 25047139
Drug: Navitoclax 250
Normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax 250 mg
Study: 25047139
Drug: Navitoclax 250
Normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax 250 mg with Rifampin 600 mg QD
Study: 22951358
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion in combination with low dose eptifibatide infusion
Study: 22951358
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion + eptifibatide
Study: 11443167
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (40 g soy protein, 118 mg isoflavones)
Study: 8825533
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg tablets on the night before and the morning of surgery, plus isotonic saline 0.3 ml iv before surgery ended.
Study: 8825533
Drug: Droperidol 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.75 mg iv injected before the operation ended.
Study: 3936140
Drug: Almitrine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (200 mg/day for 9 days)
Study: 19122308
Drug: Nocturnal home
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nocturnal home oxygen therapy (HOT)
Study: 18218179
Drug: Exenatide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (5 mcg twice daily for 4 weeks, then 10 mcg thereafter)
Study: 18218179
Drug: Insulin analogue
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogue therapy (glargine or biphasic insulin aspart)
Study: 15721095
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and glycoprotein IIb/IIIa inhibition
Study: 10789879
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg smoked cocaine
Study: 1495889
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg adinazolam mesylate immediate-release (CT) tablets
Study: 1495889
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg sustained-release (SR) tablets
Study: 1495889
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg CT tablets every 8 hr
Study: 1495889
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg SR tablets every 12 hr
Study: 30105400
Drug: Daily teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily teriparatide injection (20-μg)
Study: 30105400
Drug: Weekly teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly teriparatide injection (56.5-μg)
Study: 27144848
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral cholera vaccine Shanchol
Study: 25151225
Drug: Intravenous MVA85A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous MVA85A
Study: 20131030
Drug: Yiqi Yangyin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Yangyin Decoction (YQYYD) with conventional therapy of Western medicine
Study: 20131030
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy of Western medicine
Study: 17542349
Drug: Sarizotan 5-25
Normalized name: Sarizotan
DrugBank: Sarizotan (DB06454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarizotan 5-25 mg single doses
Study: 17542349
Drug: Sarizotan 10
Normalized name: Sarizotan
DrugBank: Sarizotan (DB06454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarizotan 10 and 20 mg b.i.d. multiple doses
Study: 17542349
Drug: Sarizotan 5
Normalized name: Sarizotan
DrugBank: Sarizotan (DB06454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarizotan 5 mg b.i.d. multiple doses
Study: 15007784
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (300 mg/d, with initial run-in of 150 mg/d for the first three days)
Study: 11727145
Drug: Clonidine 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 4.5 mg/kg
Study: 8387697
Drug: Combined radiotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radiotherapy with fast neutrons (average dose 569 cGy) and photons (average dose 36.86 Gy)
Study: 8387697
Drug: Boost therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boost therapy or mixed beam therapy with localized fast neutron field
Study: 3308650
Drug: TDB 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDB 120 mg quid
Study: 3308650
Drug: cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 400 mg tid
Study: 3308650
Drug: cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 400 mg with meals plus 800 mg at bedtime
Study: 25776457
Drug: GP IIb/IIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP IIb/IIIa receptor inhibitors
Study: 18159027
Drug: Indomethacin tablet
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin tablet
Study: 16335913
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate (2 mg) and dienogest (2 mg)
Study: 9797910
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D supplementation (1 g calcium carbonate and 14 micrograms vitamin D3)
Study: 8586825
Drug: Diuretics (altizide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (altizide and spironolactone)
Study: 9767545
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist (verapamil)
Study: 1116382
Drug: Rimiterol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimiterol (0.5 mg)
Study: 3899082
Drug: Salbutamol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.2 mg)
Study: 29262813
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg (ARB)
Study: 29262813
Drug: ARB +
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB + Hydrochlorothiazide 25 mg (HCT)
Study: 29262813
Drug: ACE inhibition
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibition (Lisinopril 40 mg/day)
Study: 29262813
Drug: Dual RAASi
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual RAASi (Lisinopril 40 mg/day + Valsartan 320 mg/day)
Study: 24795092
Drug: Intravenous doripenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous doripenem (DRPM) 0.5 g three times daily
Study: 24795092
Drug: Imipenem/cilastatin (IPM/CS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (IPM/CS) 0.5 g three times daily
Study: 24795092
Drug: Intravenous doripenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous doripenem (DRPM)